Phase 3 data for Merck & Co. and Moderna’s personalized mRNA cancer vaccine intismeran autogene were presented at ESMO’s Presidential Symposium in Madrid, days after...
Media partner
The head of Buenos Aires’ Institute for Clinical Effectiveness and Health Policy says a national agency should give Argentina a common evidence base, not centralize...
On October 14, 2026, the FDA announced the Rare Disease Framework Initiative to develop a fit-for-purpose framework for rare disease drug development, led by its...
A study led by Rare Diseases International finds rare disease patients in Colombia wait an average of 25 months for a diagnosis, and up to...
The FDA on October 14 expanded Anktiva (nogapendekin alfa inbakicept-pmln) to adults with BCG-unresponsive, high-grade papillary-only non-muscle-invasive bladder cancer, as ImmunityBio works through a March...
Explore More Topics:
LATEST
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.